Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov.

Sci Rep · 2024 · PMC10808105 · PMID 38267496

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

moderately significantno p-value reported

Eculizumab, in patients with refractory AChR, also exhibited a noticeable albeit moderately significant efficacy, as demonstrated in the REGAIN study 18 .

also in 2,178 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.